apoA2

Apolipoprotein A-II (apoA-II) is the second most abundant protein component of high-density lipoprotein (HDL) and contributes substantially to HDL structure, remodeling, and lipid metabolism through its strong lipid-binding properties^[1][2]. ApoA-II influences HDL particle composition and can modify the conformation and function of apolipoprotein A-I (apoA-I), thereby affecting cholesterol transport and lipoprotein metabolism pathways^[1][2]. Mechanistically, apoA-II participates in HDL synthesis and remodeling and has been implicated in the regulation of triglyceride metabolism, cholesterol efflux, and lipoprotein particle stability^[1][3]. These functions connect apoA-II to metabolic and cardiovascular processes, and altered plasma apoA-II levels have been associated with hypertriglyceridemia, reduced HDL levels, glucose intolerance, and type 2 diabetes-related metabolic dysfunction^[1]. In disease research, apoA-II has also been investigated as a biomarker in disorders including cardiovascular disease, pancreatic cancer, amyloidosis, obesity, and insulin resistance^[1]. Compared with the closely related HDL apolipoprotein apoA-I, apoA-II exhibits higher lipid affinity and can displace apoA-I and other HDL-associated proteins under certain experimental conditions, resulting in distinct effects on HDL function and antioxidant capacity^[1]. This distinction is further emphasized by species-specific structural differences, because human apoA-II is predominantly dimeric whereas murine apoA-II is monomeric, complicating direct translation of animal findings to human biology^[1]. For experimental applications, apoA-II is widely used as a molecular marker and mechanistic target for investigating HDL remodeling, lipid transport, metabolic disease, and cardiovascular risk pathways^[1].